SC 13D

mm04-1108_13d.txt

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ENCYSIVE PHARMACEUTICALS INC.

--------------------------------------------------------------------------------

(Name of Issuer)

Common Stock, par value $0.005 per share

--------------------------------------------------------------------------------

(Title of class of securities)

29256X107

--------------------------------------------------------------------------------

(CUSIP number)

Margaret M. Foran, Esq.

Pfizer Inc.

235 East 42nd Street

New York, NY 10017

Phone (212) 573-2323

with a copy to:

Raymond O. Gietz, Esq.

Weil, Gotshal & Manges LLP

767 Fifth Avenue

New York, New York 10153

--------------------------------------------------------------------------------

(Name, address and telephone number of person authorized

to receive notices and communications)

April 1, 2008

--------------------------------------------------------------------------------

(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report

the acquisition which is the subject of this Schedule 13D, and is filing this

schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box

[_].

------------------------------------- -------------------------------

CUSIP No. 226406106 13D Page 2

------------------------------------- -------------------------------

--------------------------------------------------------------------------------

1. NAME OF REPORTING PERSON: PFIZER INC.

--------------------------------------------------------------------------------

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a)[X]

(b)[_]

--------------------------------------------------------------------------------

3. SEC USE ONLY

--------------------------------------------------------------------------------

4. SOURCE OF FUNDS: WC

--------------------------------------------------------------------------------

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM

2(d) OR 2(e): [_]

--------------------------------------------------------------------------------

6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

--------------------------------------------------------------------------------

7. SOLE VOTING POWER: 67,688,555

(See Item 5)

NUMBER OF --------------------------------------------------------------

SHARES 8. SHARED VOTING POWER: -0-

BENEFICIALLY

OWNED BY --------------------------------------------------------------

EACH 9. SOLE DISPOSITIVE POWER: 67,688,555

REPORTING (See Item 5)

PERSON WITH --------------------------------------------------------------

10. SHARED DISPOSITIVE POWER: -0-

--------------------------------------------------------------------------------

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 67,688,555

(See Item 5)

--------------------------------------------------------------------------------

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

[_]

--------------------------------------------------------------------------------

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 83.61%

(See Item 5)

--------------------------------------------------------------------------------

14. TYPE OF REPORTING PERSON: CO

--------------------------------------------------------------------------------

------------------------------------- -------------------------------

CUSIP No. 226406106 13D Page 3

------------------------------------- -------------------------------

--------------------------------------------------------------------------------

1. NAME OF REPORTING PERSON: EXPLORER ACQUISITION CORP.

--------------------------------------------------------------------------------

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:

(a)[X]

(b)[_]

--------------------------------------------------------------------------------

3. SEC USE ONLY

--------------------------------------------------------------------------------

4. SOURCE OF FUNDS: AF

--------------------------------------------------------------------------------

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM

2(d) OR 2(e): [_]

--------------------------------------------------------------------------------

6. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

--------------------------------------------------------------------------------

7. SOLE VOTING POWER: 67,688,555

(See Item 5)

NUMBER OF --------------------------------------------------------------

SHARES 8. SHARED VOTING POWER: -0-

BENEFICIALLY

OWNED BY --------------------------------------------------------------

EACH 9. SOLE DISPOSITIVE POWER: 67,688,555

REPORTING (See Item 5)

PERSON WITH --------------------------------------------------------------

10. SHARED DISPOSITIVE POWER: -0-

--------------------------------------------------------------------------------

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 67,688,555

(See Item 5)

--------------------------------------------------------------------------------

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES:

[_]

--------------------------------------------------------------------------------

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 83.61%

(See Item 5)

--------------------------------------------------------------------------------

14. TYPE OF REPORTING PERSON: CO

--------------------------------------------------------------------------------

This statement on Schedule 13D is filed by Pfizer Inc. ("Pfizer"), and

its wholly-owned subsidiary, Explorer Acquisition Corp. ("Explorer" or the

"Purchaser"), and relates to the common stock, including the associated

preferred stock purchase rights ("Common Stock"), $0.005 par value per share, of

Encysive Pharmaceuticals Inc., a Delaware corporation ("Encysive" or the

"Company").

ITEM 1. SECURITY AND ISSUER.

The title and class of equity securities to which this statement on

Schedule 13D relates is the Common Stock of the Company. The Company's principal

executive offices are located at 4848 Loop Central Drive, Suite 700 Houston,

Texas 77081.

ITEM 2. IDENTITY AND BACKGROUND.

(a) - (c) and (f) This statement on Schedule 13D is being filed by

Pfizer, a Delaware corporation, and Explorer, a Delaware corporation. Pfizer and

Explorer are sometimes herein referred to collectively as the "Reporting

Persons," and each as a "Reporting Person." The principal executive offices of

Pfizer and Explorer are located at 235 East 42nd Street, New York, NY 10017.

Pfizer is a research-based, global pharmaceutical company. Explorer was formed

by Pfizer to acquire Encysive and has not conducted any unrelated activities

since its organization.

Set forth on Schedule I to this statement on Schedule 13D and

incorporated herein by reference is the following information with respect to

each director and executive officer of Pfizer and Explorer:

(1) name;

(2) business address;

(3) principal occupation or employment and the name, principal

business and address of any corporation or other organization in

which such employment is conducted; and

(4) citizenship

(d) - (e) During the past five years, neither of the Reporting Persons

nor, to the best knowledge of the Reporting Persons, any of the directors and

executive officers of the Reporting Persons, (1) has been convicted in a

criminal proceeding (excluding traffic violations and similar misdemeanors) or

(2) was a party to a civil proceeding of a judicial or administrative body of

competent jurisdiction and as a result of such proceeding were or are subject to

a judgment, decree or final order enjoining future violations of, or prohibited

or mandating activities subject to, U.S. federal and state securities laws or

finding any violations with respect to such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

The information set forth in Section 9 entitled "Source and Amount of

Funds" of the Offer to Purchase (as defined in Item 4) is incorporated herein by

reference.

ITEM 4. PURPOSE OF TRANSACTION.

(a) - (j) The Reporting Persons and Encysive entered into an Agreement

and Plan of Merger, dated February 20, 2008 (the "Merger Agreement"), for the

purposes of the Reporting Persons' acquisition of all of the issued and

outstanding shares of Common Stock (the "Shares"). Pursuant to the Merger

Agreement, Pfizer and Explorer commenced a tender offer (the "Offer") to

purchase all of the outstanding Shares at a purchase price of $2.35 per Share,

net to the seller in cash, without interest and less any required withholding

taxes, upon the terms and subject to the conditions set forth in the Offer to

Purchase, dated March 4, 2008 (the "Offer to Purchase"), incorporated by

reference from Exhibit (a)(1)(A) of the Tender Offer Statement on Schedule TO

filed by Explorer and Pfizer with the Securities and Exchange Commission (the

"Commission") on March 4, 2008 (as amended, the "Schedule TO"), and the related

Letter of Transmittal, incorporated by reference from Exhibit (a)(1)(B) of the

Schedule TO. After consummation of the Offer, the Merger Agreement provides that

Explorer will be merged (the "Merger") with and into Encysive, with Encysive

surviving the Merger as a wholly-owned subsidiary of Pfizer. Each Share

outstanding immediately prior to the effective time of the Merger (other than

Shares held by Encysive, Pfizer or their wholly-owned subsidiaries, all of which

will be cancelled and retired and shall cease to exist, or by stockholders who

exercise appraisal rights under Delaware law), will be converted in the Merger

into the right to receive $2.35 per Share, without interest and less any

required withholding taxes.

The information set forth in the sections of the Offer to Purchase

entitled "Summary Term Sheet," "Introduction," "Price Range of Shares;

Dividends," "Certain Effects of the Offer," "Background of the Offer; Past

Contacts or Negotiations," "Purpose of the Offer; Plans for Encysive," "The

Merger Agreement" and "Dividends and Distributions" is incorporated herein by

reference.

Except as set forth in this statement (including any information

incorporated by reference) and in connection with the transaction described

above, none of the Reporting Persons has any plan or proposal that related to or

would result in any of the transactions described in subparagraphs (a) through

(j) of Item 4 to the Schedule 13D.

ITEM 5. INTERESTS IN THE SECURITIES OF THE PURCHASER.

(a) and (b) As a result of purchases of Shares pursuant to the Offer, on

April 11, 2008, Pfizer and Explorer beneficially own an aggregate 67,688,555

shares (the "Shares") of Common Stock, representing 83.61% of the outstanding

shares of Common Stock (based upon 80,955,060 Shares issued and outstanding as

of March 28, 2008, as reported to the Reporting Persons by Encysive). Pfizer and

Explorer each have sole voting and dispositive power of all the Shares by virtue

of the fact that Explorer, the record holder of the Shares, is a wholly-owned

subsidiary of Pfizer.

(c) On April 1, 2008, Explorer accepted 61,765,295 Shares for purchase,

representing the number of Shares properly tendered and not withdrawn as of the

initial expiration date for the Offer (excluding Shares subject to notices of

guaranteed delivery). Pursuant to the subsequent offering period that is

scheduled to expire on April 14, 2008 at 5:00 p.m., New York City time, as well

as Shares delivered pursuant to notices of guaranteed delivery, Explorer

purchased the following number of Shares on the following dates at the offer

price of $2.35 per Share:

-----------------------------------------------------

DATE: NUMBER OF SHARES:

-----------------------------------------------------

April 1, 2008 166,666

-----------------------------------------------------

April 2, 2008 914,512

-----------------------------------------------------

-----------------------------------------------------

April 3, 2008 1,809,663

-----------------------------------------------------

April 4, 2008 576,170

-----------------------------------------------------

April 7, 2008 2,203,420

-----------------------------------------------------

April 8, 2008 29,407

-----------------------------------------------------

April 9, 2008 12,628

-----------------------------------------------------

April 10, 2008 210,794

-----------------------------------------------------

(d) Except as set forth in this Schedule 13D, none of the Reporting

Parties has the right to receive or the power to direct the receipt of dividends

from, or the proceeds of the sale of, securities covered by the Schedule 13D.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH

RESPECT TO SECURITIES OF THE ISSUER.

The information provided in Item 4 of this Schedule 13D is incorporated

herein by reference.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.

Exhibit No. Description

----------- -----------

Exhibit 1 Agreement and Plan of Merger dated as of February

20, 2008 among Encysive Pharmaceuticals Inc.,

Pfizer Inc. and Explorer Acquisition Corp.

(incorporated herein by reference to Exhibit

(d)(1) to the Schedule TO filed by Pfizer Inc.

with the Securities and Exchange Commission on

March 4, 2008, as amended).

Exhibit 2 Offer to Purchase dated as of March 4, 2008

(incorporated herein by reference to Exhibit

(a)(1)(A) to the Schedule TO filed by Pfizer Inc.

with the Securities and Exchange Commission on

March 4, 2008, as amended).

Exhibit 3 Form of Letter of Transmittal dated as of March

4, 2008 (incorporated herein by reference to

Exhibit (a)(1)(B) to the Schedule TO filed by

Pfizer Inc. with the Securities and Exchange

Commission on March 4, 2008, as amended).

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I

certify that the information set forth in this statement is true, complete and

correct.

Dated: April 11, 2008

PFIZER INC.

By: /s/ David Reid

-------------------------------

Name: David Reid

Title: Assistant Secretary

EXPLORER ACQUISITION CORP.

By: /s/ Lawrence Miller

-------------------------------

Name: Lawrence R. Miller

Title: Vice President

SCHEDULE I

DIRECTORS AND EXECUTIVE OFFICERS OF EXPLORER AND PFIZER

1. DIRECTORS AND EXECUTIVE OFFICERS OF EXPLORER.

The name, business address, present principal occupation or employment and

material occupations, positions, offices or employment for the past five years

of each of the directors and executive officers of Explorer are set forth below.

The business address and phone number of each such director and executive

officer is c/o Pfizer Inc., 235 East 42nd Street, New York, New York 10017,

(212) 733-2323. Unless otherwise noted, all directors and executive officers

listed below are citizens of the United States.

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT

David Reid Senior Vice President and Managing Director,

Director Pfizer Inc.'s Legal Division. Mr. Reid has

lead the Licensing, Mergers and Acquisitions

and Antitrust Center of Excellence in Pfizer's

Legal Division since 2003 and oversees a number

of other functions. Mr. Reid is currently

serving as Pfizer's Interim General Counsel.

Prior to joining Pfizer in 1997, he was a

partner at the law firm of Allen & Overy.

Douglas E. Giordano Vice President, Worldwide Business Development,

President Pfizer Inc. since April 2007; Vice President,

US Planning and Business Development, Pfizer

Inc., July 2005-March 2007; Senior

Director/Team Leader, US Planning and Business

Development, Pfizer Inc., January 2003-June

2005; Director/Team Leader, US Planning and

Business Development, Pfizer Inc., January

2000-December 2002.

Lawrence R. Miller Assistant General Counsel, Licensing and

Director Business Development, Pfizer Inc., since June

Vice President 2006; Vice President and General Counsel, Enzon

Pharmaceuticals, Inc., July 2005- May 2006;

Senior Corporate Counsel, Pfizer Inc., November

2002-July 2005; Corporate Counsel, Pfizer Inc.,

October 2000-November 2002.

Joanne Smith-Farrell Senior Director, Business Development, Pfizer

Vice President Inc. since September 2007; Senior Vice

President, Business Development and Licensing,

Gene Logic Inc., February 2007-August 2007;

Vice President, Corporate Development and

Strategy, Gene Logic Inc., December

2004-February 2007; Senior Director, Strategic

Marketing, Gene Logic Inc., November

2003-December 2004; President and CEO, emGene,

Inc., August 2001-November 2003.

Susan Glimcher Tax Counsel, Pfizer Inc., since October 2001.

Vice President

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT

Susan Grant Senior Manager-Corporate Governance, Pfizer

Secretary Inc. since April 2006. Assistant Secretary of

Pfizer since April 2003. Employed by Pfizer

since June 2000 in various positions of

increasing responsibility within the Corporate

Governance group.

Kathleen R. O'Connell Director, International Treasury, Pfizer Inc

Vice President since 1995; Director, Cash Management, Pfizer

Treasurer Inc 1993-1995; Manager & Senior Manager,

International Treasury, Pfizer Inc. 1988-1993;

Senior Auditor, Pfizer Inc, 1986-1988.

2. DIRECTORS AND EXECUTIVE OFFICERS OF PFIZER

The name, business address, present principal occupation or employment and

material occupations, positions, offices or employment for the past five years

of each of the directors and executive officers of Pfizer are set forth below.

The business address and phone number of each such director and executive

officer is Pfizer Inc., 235 East 42nd Street, New York, New York 10017, (212)

733-2323. All directors and executive officers listed below are citizens of the

United States.

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Dennis A. Ausiello, M.D. The Jackson Professor of Clinical Medicine at

Director Harvard Medical School and Chief of Medicine at

Massachusetts General Hospital since 1996.

President of the Association of American

Physicians since 2006. Member of the Institute

of Medicine of the National Academy of Sciences

and a Fellow of the American Academy of Arts

and Sciences. Director of MicroCHIPS (drug

delivery technology) and Advisor to the

Chairman of the Board of TIAX (formerly Arthur

D. Little). A Director of Pfizer Inc. since

December 2006.

Michael S. Brown, M.D. Distinguished Chair in Biomedical Sciences from

Director 1989 and Regental Professor from 1985 at the

University of Texas Southwestern Medical Center

at Dallas. Co-recipient of the Nobel Prize in

Physiology or Medicine in 1985 and the National

Medal of Science in 1988. Member of the

National Academy of Sciences, the Institute of

Medicine and Foreign Member of the Royal

Society (London). Director of Regeneron

Pharmaceuticals, Inc. A Director of Pfizer

Inc. since 1996.

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

M. Anthony Burns Chairman Emeritus since May 2002, Chairman of

Director the Board from May 1985 to May 2002, Chief

Executive Officer from January 1983 to November

2000, and President from December 1979 to June

1999 of Ryder System, Inc., a provider of

transportation and logistics services. Director

of The Black & Decker Corporation, J.C. Penney

Company, Inc. and J.P. Morgan Chase & Co.

Trustee of the University of Miami. A director

of Pfizer Inc. since 1988.

Robert N. Burt Retired Chairman and Chief Executive Officer of

Director FMC Corporation, a company that manufactures

chemicals and FMC Technologies, Inc., a company

that manufactures machinery. Mr. Burt was

Chairman of the Board of FMC Corporation from

1991 to December 2001, its Chief Executive

Officer from 1991 to August 2001 and a member

of its Board of Directors since 1989. He was

Chairman of the Board of FMC Technologies,

Inc., from June 2001 to December 2001 and its

Chief Executive Officer from June 2001 to

August 2001. Director of Phelps Dodge

Corporation and Janus Capital Group, Inc. Life

Trustee of the Rehabilitation Institute of

Chicago and Chicago Symphony Orchestra, and

Director of the Chicago Public Education Fund.

A director of Pfizer Inc. since June 2000.

W. Don Cornwell Chairman of the Board and Chief Executive

Director Officer since 1988 of Granite Broadcasting

Corporation, a group broadcasting company.

Director of Avon Products, Inc. and CVS

Corporation. Also a Director of Wallace-Reader's

Digest Funds and the Telecommunications

Development Fund. Trustee of Big

Brothers/Sisters of New York and Mt. Sinai

University Medical Center. A director of Pfizer

Inc. since February 1997.

William H. Gray III President and Chief Executive Officer of The

Director College Fund/UNCF, an educational assistance

organization, since 1991. Mr. Gray served as a

Congressman from the Second District of

Pennsylvania from 1979 to 1991, and at various

times during his tenure, served as Budget

Committee Chair and House Majority Whip.

Director of Dell Computer Corporation,

Electronic Data Systems Corporation,

J.P. Morgan Chase & Co., Prudential Financial,

Inc., Rockwell Automation Inc., Viacom Inc. and

Visteon Corporation. A director of Pfizer Inc.

since June 2000.

10

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Constance J. Horner Guest Scholar since 1993 at The Brookings

Director Institution, an organization devoted to

nonpartisan research, education and publication

in economics, government and foreign policy and

the social sciences. Commissioner of the U.S.

Commission on Civil Rights from 1993 to 1998.

Served at the White House as Assistant to

President George H.W. Bush and as Director of

Presidential Personnel from August 1991 to

January 1993. Deputy Secretary, U.S.

Department of Health and Human Services from

1989 to 1991. Director of the U.S. Office of

Personnel Management from 1985 to 1989.

Director of Ingersoll-Rand Company Limited and

Prudential Financial, Inc.; Fellow, National

Academy of Public Administration; Trustee,

Annie E. Casey Foundation; Director of National

Association of Corporate Directors, Member of

the Board of Trustees of the Prudential

Foundation, Member, U.S. Department of Defense

Advisory Committee on Women in the Services. A

director of Pfizer Inc. since 1993.

William R. Howell Chairman Emeritus of J.C. Penney Company, Inc.,

Director a provider of consumer merchandise and services

through department stores, catalog departments

and the Internet, since 1997. Chairman of the

Board and Chief Executive Officer of J.C.

Penney Company, Inc. from 1983 to 1997.

Director of American Electric Power Company,

Deutsche Bank Trust Company Americas,

ExxonMobil Corporation, Halliburton Company,

The Williams Companies, Inc. and Viseon, Inc.

A director of Pfizer Inc. since June 2000.

Suzanne Nora Johnson Retired Vice Chairman, Goldman Sachs Group,

Director Inc., since January 2007. During her 21 year

tenure with Goldman Sachs, Mrs. Johnson served

in various leadership roles, including Head of

the firm's Global Healthcare Business, Head of

Global Research and Chair of the Global Markets

Institute. Director of Intuit and VISA. Board

member of the American Red Cross, Brookings

Institution, the Carnegie Institution of

Washington and the University of Southern

California. A Director of Pfizer Inc. since

September 2007.

11

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

James M. Kilts Founding Partner, Centerview Partners

Director Management, LLC, a financial advisory firm,

since 2006. Vice Chairman, The Procter &

Gamble Company, 2005-2006. Chairman and Chief

Executive Officer, The Gillette Company,

2001-2005 and President, The Gillette Company,

2003-2005. President and Chief Executive

Officer, Nabisco Group Holdings Corporation,

January 1998 until it's acquisition by Philip

Morris Companies, now Altria, in December

1999. Director of The New York Times Company,

Metropolitan Life Insurance Company and

Meadwestvaco Corporation. Trustee of Knox

College and the University of Chicago, and a

member of the Board of Overseers of Weill

Cornell Medical College. A Director of Pfizer

Inc. since September 2007 and a member of our

Compensation Committee.

George A. Lorch Chairman Emeritus of Armstrong Holdings, Inc.,

Director a global company that manufactures flooring and

ceiling materials, since August 2000. Chairman

and Chief Executive Officer of Armstrong

Holdings, Inc. from May 2000 to August 2000,

and its President and Chief Executive Officer

from September 1993 to May 1994. Chairman of

Armstrong World Industries, Inc. from May 1994

to May 2000, its President and Chief Executive

Officer from September 1993 to May 2000, and a

Director from 1988 to November 2000. On

December 6, 2000, Armstrong World Industries

Inc. filed for voluntary reorganization under

Chapter 11 of the U.S. Bankruptcy Code.

Director of Autoliv, Inc., Household

International, Inc. and The Williams

Companies. A director of Pfizer Inc. since

June 2000.

12

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Dana G. Mead Chairman of Massachusetts Institute of

Director Technology since July 1, 2003. Retired

Chairman and Chief Executive Officer of

Tenneco, Inc. Chairman and Chief Executive

Officer of Tenneco, Inc. from 1994 to 1999.

Chairman of two of the successor companies of

the Tenneco conglomerate, Tenneco Automotive

Inc. and Pactiv Corporation, global

manufacturing companies with operations in

automotive parts and packaging, from November

1999 to March 2000. Director of Zurich

Financial Services. Chairman of the Board of

the Ron Brown Award for Corporate Leadership.

Chairman of the Massachusetts Institute of

Technology Corporation and a Lifetime Trustee

of the Association of Graduates, U.S. Military

Academy, West Point. Former Chairman of the

Business Roundtable and of the National

Association of Manufacturers. A director of

Pfizer Inc. since 1998.

William C. Steere, Jr. Chairman Emeritus of Pfizer Inc. since July

Director 2001. Chairman of Pfizer's Board from 1992 to

April 2001 and Pfizer's Chief Executive Officer

from February 1991 to December 2000. Director

of Dow Jones & Company, Inc., Health Management

Associates, Inc., MetLife, Inc. and Minerals

Technologies Inc. Director of the New York

University Medical Center and the New York

Botanical Garden. Member of the Board of

Overseers of Memorial Sloan-Kettering Cancer

Center. A director of Pfizer Inc. since 1987.

Jeffrey B. Kindler Chairman of the Board and Chief Executive

Chief Executive Officer and Officer of Pfizer Inc. since 2006. Mr. Kindler

Chairman was previously Senior Vice President and

General Counsel of Pfizer Inc. from January 2002

to 2006. Prior to joining Pfizer, Mr. Kindler

served as Chairman of Boston Market Corporation,

a food service company owned by McDonald's

Corporation, from 2000 to 2001, and President of

Partner Brands, also owned by McDonald's, during

2001. He was Executive Vice President, Corporate

Relations and General Counsel of McDonald's

Corporation from 1997 to 2001, and from 1996 to

1997 served as that company's Senior Vice

President and General Counsel. Mr. Kindler was

elected to the Board of Directors and appointed

Chairman of the Executive Committee effective

July 31, 2006.

13

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Frank A. D'Amelio Senior Vice President and Chief Financial

Senior Vice President and Officer of Pfizer Inc. since September 2007.

Chief Financial Officer Mr. D'Amelio served as Chief Administrative

Officer and Senior Executive Vice President

Integration of Alcatel-Lucent since December

2006; Chief Operating Officer of Lucent

Technologies from January 2006 through November

2006; and Executive Vice President,

Administration, and Chief Financial Officer of

Lucent Technologies from May 2001 until January

2006. Mr. D'Amelio began his career in 1979 at

Bell Labs, where he held a variety of financial,

accounting and general management positions.

Ian C. Read Senior Vice President; President, Worldwide

Senior Vice President; Pharmaceutical Operations, since August 2006.

President, Mr. Read has held various positions of

Worldwide Pharmaceutical increasing responsibility in pharmaceutical

Operations operations. He previously served as Area

President, Europe, Canada, Africa and Middle

East, Senior Vice President of the Pfizer

Pharmaceuticals Group, and Executive Vice

President of Europe and Canada. In July 2002

he was appointed President-Europe and Canada.

Mr. Read served as President of the Latin

American region and was elected a Vice

President of Pfizer Inc. in April 2001. Mr.

Read, a member of the Pfizer Executive

Leadership Team, joined Pfizer Inc. in 1978.

Richard H. Bagger Senior Vice President, Worldwide Public Affairs

Senior Vice President, and Policy, since August 2006. Since joining

Worldwide Public Affairs and Pfizer in 1993, Mr. Bagger has held various

Policy positions of increasing responsibility in

Pfizer's Corporate Affairs Division. He was

promoted to Vice President, Government Relations

in 2002 and to Senior Vice President, Government

Relations in 2003. He assumed additional

responsibility for Public Affairs and Policy in

2005. Prior to joining Pfizer, he was Assistant

General Counsel of Blue Cross and Blue Shield of

New Jersey and previously practiced law with the

firm of McCarter and English. Mr. Bagger also

served in both houses of the New Jersey

legislature.

14

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Joseph M. Feczko Senior Vice President and Chief Medical Officer

Senior Vice President and of Pfizer Inc. since August 2006. Dr. Feczko

Chief Medical Officer has held various positions of increasing

responsibility in research and development and

medical and regulatory operations. After four

years as Medical Director at Glaxo's Research &

Development headquarters in London, Dr. Feczko

returned to Pfizer in 1996 and was promoted to

the position as Senior Vice President, Medical

and Regulatory Operations for Global

Pharmaceuticals. He became Chief Medical

Officer in 2002. Dr. Feczko, who is

board-certified in Internal Medicine and a

specialist in infectious diseases, originally

joined Pfizer in 1982.

Martin Mackay Senior Vice President; President of Pfizer

Senior Vice President; Global Research & Development since October

President, Pfizer Global 2007. Early in 2007, he was named Vice

Research & Development President, Pfizer Global Research &

Development, Head of Worldwide Development. In

2003, he held the position of Senior Vice

President, Head of Worldwide Research and

Technology. In 1999, he was the Senior Vice

President, Head of Worldwide Discovery. In

1998, he held the position of Vice President,

UK Discovery and, in 1997, he was the Senior

Director, Head of Biology. Dr. Mackay joined

Pfizer in 1995.

Mary McLeod Senior Vice President of Pfizer's Worldwide

Senior Vice President, Human Resources, since April 2007. Ms. McLeod

Worldwide Human Resources served in this role on an interim basis from

January to April while she was a consultant at

Korn Consulting Group. Prior to that, she led

Human Resources for Symbol Technologies from

2005 to 2007 and was the head of Human Resources

for Charles Schwab, from 2001 to 2004. From 1999

to 2001, she was Vice President-Human Resources

for Cisco Systems and prior to that, Vice

President of Human Resources for General

Electric Company from 1992 to 1997.

Natale S. Ricciardi Senior Vice President; President, Pfizer Global

Senior Vice President; Manufacturing since October 2004. He held a

President, Pfizer Global number of positions of increasing

Manufacturing responsibility in manufacturing before being

named U.S. Area Vice President/Team Leader for

Pfizer Global Manufacturing in 1999. Mr.

Ricciardi joined us in 1972. He is a Director

of Mediacom Communications Corp.

15

NAME AND POSITION PRESENT PRINCIPAL OCCUPATION OR EMPLOYMENT AND

EMPLOYMENT HISTORY

Sally Susman Senior Vice President - Worldwide

Senior Vice President - Communications and Chief Communications Officer

Worldwide Communications, and since February 2008. Prior to joining Pfizer,

Chief Communications Officer Ms. Susman held senior level positions at The

Estee Lauder Companies, including Executive Vice

President from December 2004 to January 2008 and

Senior Vice President - Global Communications

from September 2000 through November 2004.

Earlier in her career, Ms. Susman was

responsible for all of American Express

International's internal communications and

governmental affairs and spent eight years in

government service focused on international

trade issues.

16